

# Berberine: Best Alternative Medicine Insight Abating Global Challenges for Treatment of MRSA Infections – Response to Comments of Savita V Jadhav [Response to Letter]

Shuai Xia<sup>1</sup>, Liyan Ma<sup>2</sup>, Guoxing Wang<sup>1</sup>, Jie Yang<sup>1</sup>, Meiyong Zhang<sup>3</sup>, Xuechen Wang<sup>1</sup>, Jianrong Su<sup>2</sup>, Miaorong Xie<sup>1</sup>

<sup>1</sup>Department of Emergency and Critical Care Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China; <sup>2</sup>Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China;

<sup>3</sup>Department of Emergency Center, Peking University First Hospital, Peking University, Beijing, 100050, People's Republic of China

Correspondence: Miaorong Xie, Department of Emergency and Critical Care, Center, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong'an Road, Xicheng District, Beijing, 100050, People's Republic of China, Email [xiemiao27@126.com](mailto:xiemiao27@126.com)

## Dear editor

Thanks to Dr. Savita V Jadhav and the medical staff for their interest in our article.<sup>1</sup> We would like to make it clear about the specific comments.

Firstly, the concern regarding “the CLSI guidelines in methodology with reference number 19” may be the result of a misunderstanding. In the context, what we mentioned was that the MIC determination method was recommended by CLSI guideline rather than why RIF and CLI were selected to be tested. Secondly, the comments about RIF prescription should be avoided in diseases other than Mycobacterial diseases are very constructive. Currently, our research remains at the laboratory stage; it is necessary to put into practice in vivo to evaluate the clinical effects because the RIF alone is rarely used to treat MRSA. However, no papers or guidelines show that the RIF cannot treat MRSA infection. According to the updated MRSA treatment guidelines from UK,<sup>2</sup> RIF is recommended in combination with other agents to treat MRSA infections. Our study found that berberine in combination with RIF has an excellent synergistic effect which is not in conflict with clinical application. Furthermore, the synergistic activities in vivo are on-going and it is our pleasure to improve the clinical practices expanding RIF indication if the experimental results are satisfactory. Lastly, regarding your advice for us to further evaluate other synergistic effects with oxacillin, azithromycin and levofloxacin as well as additive effects with ampicillin and cefazolin, these have already been reported in previous studies.<sup>3,4</sup> We consider it a meaningful proposal and will perform the experiments in vivo in the near future.

## Disclosure

The authors report no conflicts of interest in this communication.

## References

1. Xia S, Ma L, Wang G, et al. In vitro antimicrobial activity and the mechanism of berberine against methicillin-resistant staphylococcus aureus isolated from bloodstream infection patients. *Infect Drug Resist.* 2022;15:1933–1944. doi:10.2147/IDR.S357077
2. Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. *JAC Antimicrob Resist.* 2021;3(1):dlaa114. doi:10.1093/jacamr/dlaa114
3. Yu HH, Kim KJ, Cha JD, et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. *J Med Food.* 2005;8(4):454–461. doi:10.1089/jmf.2005.8.454
4. Zuo GY, Li Y, Han J, Wang GC, Zhang YL, Bian ZQ. Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). *Molecules.* 2012;17(9):10322–10330. doi:10.3390/molecules170910322

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Infection and Drug Resistance 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Infection and Drug Resistance editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

## Infection and Drug Resistance

Dovepress

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

<https://doi.org/10.2147/IDR.S376794>